Powerful clot-blocking drug fails to beat standard pills in stubborn stroke subtype
A multicenter phase III trial found that intravenous tirofiban did not outperform standard oral antiplatelet therapy for 90-day functional outcomes ...
A multicenter phase III trial found that intravenous tirofiban did not outperform standard oral antiplatelet therapy for 90-day functional outcomes ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine